PernaA.F., IngrossoD., LombardiC.Homocysteine in Uremia. Am J Kidney Dis2003; 41(suppl): S123–6.
4.
BostomA.G., LathropL.Hyperhomocysteinemia in end stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int1997; 52: 10–20.
5.
DennisV.W., RobinsonK.Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int1996; 50(suppl): S11–7.
FoleyR.N., ParfreyP.S., SamakM.J.Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis2001; 32(suppl): S112–9.
8.
PernaA.F., IngrossoD., De SantoN.G.Metabolic consequences of folate induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol1997; 8: 1899–905.
9.
BostomA.G., SheminD., VerhoefP.Elevated fasting total plasma homocyteine levels and cardiovascular disease outcomes in dialysis patients. Arterioscler Thromb Vasc Biol1977; 17: 2554–8.
10.
MoustaphaA., NasoA., NahlawiM.Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end stage renal disease. Circulation1998; 97: 138–41.
BucciantiG., BaragettiI., BamontiF.Plasma homocysteine levels and cardiovascular mortality in patients with end stage renal disease. J Nephrol2004; 17: 405–10.
13.
LibettaC., ZucchiM., GoriE.Prevalence of hyperhomocysteinemia in hemodialysis patients. Kidney Int2003; 64: 1531.
14.
DabbaghS., CarrolK.Homocysteine levels in children mantained on chronic hemodialysis (Abstract). Am J Soc Nephrol2001; 12: A4245.
15.
LilienM., DuranM., Van HoeckK.Hyperhomocysteinemia in children with chronic renal failure. Nephrol Dial Transplant1999; 14: 366–8.
16.
Van BeynumI.M., SmeitinkJ.A., Den HeijerM.Hyperhomocysteinemia: A risk factor for ischemic stroke in children. Circulation1999; 72: 324–32.
17.
SulimanM.E., AnderstamB., LindholmB.Total, free, and protein bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant1997; 12: 2332–8.
18.
SulimanM.E., QureshiA.R., BaranyP.Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int2000; 57: 1727–35.
19.
Kalantar-ZadehK., BlockG., HumphreysM.H.Revers epidemiology of cardiovascular risk factor in maintenance dialysis patients. Kidney Int2003; 63: 793–808.
20.
SulimanM.E., StenvinkelP., QureshiA.R.Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis2004; 44: 455–65.
21.
BuschM., FrankeS., MullerA.Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C- reactive protein. Kidney Int2004; 66: 338–47.
22.
Kalantar-ZadehK., BlockG., HumpherysM.H.A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. Am J Soc Nephrol2004; 15: 442–53.
23.
HouseA.A., WellsG.A., DonnellyJ.G.Randomized trial of high-vs.low-flux haemodialysis: Effects on homocysteine and lipids. Nephrol Dial Transplant2000; 15: 1029–34.
24.
LasseurC., ParrotF., DelmasY.Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism. J Nephrol2001; 14: 32–5.
25.
BaragettiI., BamontiF., PatrossoF.Influenza dell'acetate Free Biofiltration (AFB) sui livelli di omocisteina in pazienti uremici. G Ital Nefrol2001; 18: 695–700.
26.
van TellingenA., GrootemanP.C.M., BartelsP.C.M.Long term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int2001; 59: 342–7.
27.
De Vries AnS., LangloisM., BernardD.Effect of dialyser membrane pore size on plasma homocysteine levels in hemodialysis patients. Nephrol Dial Transplant2003; 18: 2596–600.
28.
GonellaM., CalabreseG., MengozziA.The achievement of normal homocysteinemia in regular extracorporeal dialysis patients. J Nephrol2004; 17: 411–3.
29.
SplendianiG., De AngelisS., TullioT.Selective adsorption of homocysteine using an HFR-ON LINE technique. Artif Organs2004; 28: 592–7.
